Erratum
In the Review entitled “Iclaprim” by Stephan A Kohlhoff & Roopali Sharma, published in the September 2007 issue of Expert Opinion on Investigational Drugs (Expert Opin. Investig. Drugs (2007) 16(9):1441–1448), it has been brought to our attention that the following sentence in the penultimate paragraph of Section 4 should have been removed as this is an erroneous repetition from a previous paragraph referring to Phase II study results, and does not reflect ASSIST-2 (Phase III) study results as implied by this sentence:
In ASSIST-2, iclaprim 0.8 mg/kg or 1.6 mg/kg were compared with vancomycin. Eradication rates were comparable for all organisms, but were higher for S. aureus (72 – 80% for iclaprim versus 59% for vancomycin), including 5 cases of MRSA (4 in the iclaprim group, all of which were eradicated) [101].
We apologise for any inconvenience this may have caused our readers.